A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA